Search results
Results From The WOW.Com Content Network
Pioglitazone (Actos), France and Germany have suspended its sale after a study suggested the drug could raise the risk of bladder cancer. [8] Rosiglitazone (Avandia), which was put under selling restrictions in the US and withdrawn from the market in Europe due to some studies suggesting an increased risk of cardiovascular events. Upon re ...
Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. [1] [2] It is used together with a diabetic diet and exercise. [1] [2] It is not indicated for use by itself in type 1 diabetes. [1] [2] It is taken by mouth.
Researchers in Spain wanted to know if the Mediterranean diet might help reduce the risk factors for metabolic syndrome and metabolic disorders in people with long COVID. They published their ...
Patients who take glucagon-like peptide 1 (GLP-1) receptor agonists may be at increased risk of aspiration during anesthesia due to delayed gastric emptying, according to case reports. In 2023, the American Society of Anesthesiologists suggested holding the GLP-1 agonists on the day of the procedure/surgery or a week earlier.
Increase the risk of heart failure; Cause an average of 2–5 kg weight gain; Are associated with a higher risk of edema, anemia and bone fractures; Can increase low-density lipoprotein; Rosiglitazone has been linked to increased triglycerides and an increased risk of a heart attack; Pioglitazone has been linked to an increased risk of bladder ...
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...
Traditional risk factors for heart disease include obesity, diabetes, high blood pressure and high cholesterol levels. Testing for Lp(a) and CRP can reveal less obvious risk factors.
It was found that Acarbose appeared to reduce incidence of diabetes mellitus type 2 when compared to placebo, however there was no conclusive evidence that acarbose compare to diet and exercise, metformin, placebo, no intervention improved all-cause mortality, reducer or increased risk of cardiovascular mortality, serious or non-serious adverse ...